NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

造血干细胞移植市场:各移植类型、适应症、应用、地区的市场规模、占有率、展望、机会分析 (2020~2027年)

Hematopoietic Stem Cell Transplantation Market, by Transplant Type, by Indication, by Application and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品编码 995624
出版日期 内容资讯 英文 208 Pages
商品交期: 2-3个工作天内
价格
造血干细胞移植市场:各移植类型、适应症、应用、地区的市场规模、占有率、展望、机会分析 (2020~2027年) Hematopoietic Stem Cell Transplantation Market, by Transplant Type, by Indication, by Application and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2021年02月02日内容资讯: 英文 208 Pages
简介

全球造血干细胞移植 (HSCT)的市场规模,由于白血病和淋巴瘤的盛行率上升,在预测期间内预计大幅度成长。根据世界卫生组织(WHO),在全球每年进行超过50,000件的造血干细胞移植,数量预计逐年增加。

还有根据Center for Disease Control and Prevention (CDC),美国2013年约有45,360人诊断出白血病,23,549人死亡(男性13,625人,女性9,924人)。根据该中心,这个疾病女性比男性大量。白血病,占全部的癌症新病例数的约3%。

本报告提供全球造血干细胞移植 (HSCT) 市场相关调查分析,市场概要,各市场区隔的市场分析,各地区、国家的市场分析,竞争情形等相关的系统性资讯。

目录

第1章 调查目的、前提条件

第2章 市场概要

  • 报告的说明
    • 市场定义和范围
  • 摘要整理
    • 市场明细:各移植类型
    • 市场明细:各适应症
    • 市场明细:各应用领域
    • 市场明细:各地区
  • Coherent Opportunity Map (COM)

第3章 市场动态,法规,及趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 主要的发展
  • 开发平台分析
  • PEST分析
  • 偿付方案
  • 法规方案
  • 流行病学
  • 政府的积极推动
  • 治疗流程

第4章 COVID-19的影响分析

  • COVID-19流行病学
  • 造血干细胞移植(HSCT)中COVID-19管理的指南
  • COVID-19对临床试验的影响

第5章 全球造血干细胞移植 市场:各移植类型

  • 简介
  • 自体
  • 同种异体

第6章 全球造血干细胞移植 市场:各适应症

  • 简介
  • 急性骨髓性白血病(AML)
  • 急性淋巴芽球性白血病(ALL)
  • 何杰金氏淋巴瘤(HL)
  • 非何杰金氏淋巴瘤(NHL)
  • 多发性骨髓瘤(MM)
  • 其他非恶性疾病

第7章 全球造血干细胞移植 市场:各应用领域

  • 简介
  • 骨髓移植(BMT)
  • 周边血液干细胞移植(PBSCT)
  • 脐带血移植(CBT)

第8章 全球造血干细胞移植 市场:各地区

  • 简介
  • 北美
  • 欧洲
  • 南美
  • 亚太地区
  • 中东
  • 非洲

第9章 竞争情形

  • 企业简介
    • Pluristem Therapeutics Inc.
    • CellGenix GmbH
    • Regen Biopharma Inc.
    • Lonza Group
    • Kiadis Pharma
    • Taiga Biotechnologies, Inc.
    • Takeda Pharmaceutical Company Limited
    • Escape Therapeutics, Inc.
    • Bluebird Bio
    • Talaris Therapeutics, Inc.
    • Marker Therapeutics Inc.
    • Stempeutics Research Pvt Ltd.

第10章 Section

目录

Title:
Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type (Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), and Other Non-malignant Disorders), by Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), and Cord Blood Transplant (CBT))and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources; 1) autologous, that uses stem cells from the patient's own body, 2) and allogeneic that sources stem cells from a donor's body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Market Dynamics

The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma. According to Center for Disease Control and Prevention (CDC), in the U.S., around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). According to the same source the condition is more prevalent among men than women. Leukemia accounts for around 3% of all new cancer cases.

Key features of the study:

  • This report provides in-depth analysis of the global hematopoietic stem cell transplantation market, market size (US$ Mn), and compound annual growth rate (CAGR %) for the forecast period 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hematopoietic stem cell transplantation market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global hematopoietic stem cell transplantation market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the hematopoietic stem cell transplantation market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type:
  • Allogeneic
  • Autologous
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Transplant Type:
  • Allogeneic
  • Autologous
    • By Indication:
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
    • By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Transplant Type:
  • Allogeneic
  • Autologous
    • By Indication:
  • Acute Myeloid Leukaemia (AML)
  • Acute Lymphoblastic Leukaemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
    • By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Transplant Type:
  • Allogeneic
  • Autologous
    • By Indication:
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
    • By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Transplant Type:
  • Allogeneic
  • Autologous
    • By Indication:
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
    • By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Transplant Type:
  • Allogeneic
  • Autologous
    • By Indication:
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
    • By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Transplant Type:
  • Allogeneic
  • Autologous
    • By Indication:
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin Lymphoma (NHL)
  • Multiple Myeloma (MM)
  • Other Non-Malignant Disorders
    • By Application:
  • Bone Marrow Transplant (BMT)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Cord Blood Transplant (CBT)
  • Company Profiles
    • Pluristem Therapeutics Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • CellGenix GmbH
    • Regen Biopharma Inc.
    • Lonza Group
    • Kiadis Pharma
    • Taiga Biotechnologies, Inc.
    • Takeda Pharmaceutical Company Limited
    • Escape Therapeutics, Inc.
    • Bluebird Bio
    • Talaris Therapeutics, Inc.
    • Marker Therapeutics Inc.
    • Stempeutics Research Pvt Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Transplant Type
    • Market Snippet, By Indication
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • Pipeline Analysis
  • PEST Analysis
  • Reimbursement Scenario
  • Regulatory Scenario
  • Epidemiology
  • Government Initiatives
  • Treatment Algorithm

4. Impact Analysis of COVID-19

  • COVID-19 Epidemiology
  • Guidelines for COVID-19 Management in Hematopoietic Stem Cell Transplantation (HSCT)
  • Impact of COVID-19 on Clinical Trials

5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Autologous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Allogeneic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Acute Myeloid Leukemia (AML)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Acute Lymphoblastic Leukemia (ALL)
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hodgkin lymphoma (HL)
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Non-Hodgkin Lymphoma (NHL)
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Multiple Myeloma (MM)
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Other Non-malignant Disorders
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Bone Marrow Transplant (BMT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Peripheral Blood Stem Cells Transplant (PBSCT)
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Cord Blood Transplant (CBT)
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Latin America
    • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Asia Pacific
    • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Company Profiles
    • Pluristem Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • CellGenix GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Regen Biopharma Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lonza Group
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Kiadis Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Taiga Biotechnologies, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Escape Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bluebird Bio
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Talaris Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Marker Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Stempeutics Research Pvt Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact